NASDAQ · CAMP
Healthcare · Biotechnology
$4.20
Down-$0.13 (-3.00%)
Updated Nov 12, 2026, 11:19 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CAMP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 11, 2026
CAMP closed at $4.20 after 21 trading sessions, up 22.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 11, 2026 | $4.41 | $4.415 | $4.13 | $4.20 | 95.22K |
| Nov 10, 2026 | $4.63 | $4.63 | $4.25 | $4.33 | 109.02K |
| Nov 9, 2026 | $4.16 | $4.97 | $3.9895 | $4.69 | 374.45K |
| Nov 6, 2026 | $3.72 | $4.06 | $3.66 | $4.06 | 128.68K |
| Nov 5, 2026 | $3.80 | $3.875 | $3.54 | $3.72 | 191.11K |
| Nov 4, 2026 | $4.01 | $4.01 | $3.73 | $3.74 | 126.77K |
| Nov 3, 2026 | $3.82 | $4.00 | $3.79 | $3.83 | 134.4K |
| Nov 2, 2026 | $4.02 | $4.15 | $3.71 | $3.775 | 171.22K |
| Oct 30, 2026 | $3.87 | $4.005 | $3.775 | $3.96 | 138K |
| Oct 29, 2026 | $3.69 | $3.9899 | $3.66 | $3.90 | 151.98K |
| Oct 28, 2026 | $3.65 | $3.66 | $3.48 | $3.65 | 99.17K |
| Oct 27, 2026 | $3.26 | $3.755 | $3.25 | $3.65 | 260.82K |
| Oct 26, 2026 | $3.32 | $3.32 | $3.19 | $3.21 | 60.11K |
| Oct 23, 2026 | $3.39 | $3.39 | $3.21 | $3.30 | 284.95K |
| Oct 22, 2026 | $3.20 | $3.50 | $3.195 | $3.39 | 141.13K |
| Oct 21, 2026 | $3.17 | $3.33 | $2.96 | $3.29 | 186.41K |
| Oct 20, 2026 | $3.18 | $3.38 | $3.11 | $3.16 | 89.17K |
| Oct 19, 2026 | $3.20 | $3.41 | $3.11 | $3.14 | 57.71K |
| Oct 16, 2026 | $3.45 | $3.45 | $3.17 | $3.17 | 92.42K |
| Oct 15, 2026 | $3.46 | $3.54 | $3.43 | $3.45 | 56.26K |
| Oct 14, 2026 | $3.33 | $3.445 | $3.17 | $3.43 | 155.72K |
The latest Smart Investors Daily articles mentioning CAMP.
Company
Market Activity
Research & News
CAMP research
Company profile and research snapshot.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | Raymond James | Strong Buy | — |
| Oct 15, 2026 | Needham | Buy | — |
| Oct 5, 2026 | Oppenheimer | Outperform | — |
| Sep 29, 2026 | Chardan Capital | Buy | — |
| Aug 14, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 27, 2026
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 Company on track to initiate ASCEND clinical trial in 4Q 2026 WATERTOWN, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to u
Benzinga · Oct 27, 2026
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company on track to
Benzinga · Oct 23, 2026
Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAMP.
